Arthur Hayes returns to the spotlight with a significant move: joining the board and acquiring a substantial stake in a company active in the stem cell sector, with the declared goal of tapping into the longevity trend that attracts capital even from the crypto world. The change of scenario would come after a supposed presidential pardon that would have eased operational constraints and redefined his public profile following the well-known events related to BitMEX.
According to the data collected by the editorial team, based on research in public records and corporate communications available as of August 21, 2025, there is still no official statement explicitly naming the company involved or the exact percentage of the stake. The industry analysts we consulted note that it is relatively common for crypto family offices to adopt diversify-in-healthcare strategies before formal announcements to the media. In our analysis of public filings (e.g., SEC’s EDGAR database) and registrations in foreign jurisdictions, no public confirmation documents have yet emerged regarding the formal entry into the board.
From trading to biomedicine: what Arthur Hayes is doing
The co-founder of BitMEX is reportedly reallocating part of the capital towards regenerative medicine, taking on a governance role and acquiring a stake in a company that offers stem cell-based treatments. It should be noted that the information is still partial. According to some rumors, Arthur Hayes has been attending clinics in Mexico and Thailand for over a year, exploring protocols aimed at improving metabolic health and preventing aging.
What we know so far (and what remains to be clarified)
- Role: presence on the board of directors of the company (company name to be verified);
- Participation: investment described as “relevant” (official percentages are not available);
- Direct experience: it is rumored that Hayes has received treatments at the same facility where he invests, information yet to be confirmed with official sources;
- Declared objective: aim to extend health in old age rather than “prolonging the years” at any cost.
Why crypto capital looks at longevity
The wealth created in the digital ecosystem is observing with growing interest high asymmetry verticals between risk and impact. Biogerontology falls into this category. In this context, crypto finance is accustomed to rapid innovation cycles: a mindset that combines with frontier biotech.
- Vitalik Buterin has supported projects and foundations committed to the study of aging, including the SENS Research Foundation;
- Brian Armstrong is among the supporters of NewLimit, a startup focused on cellular reprogramming for longevity;
- Balaji Srinivasan is known for his views on the integration between digital technology and emerging sectors, although the reference to his participation in companies like Counsyl (now part of Myriad Genetics) is not confirmed.
- Family office crypto: they support traditional venture capitalists in early-stage rounds and pre-clinical investments in ATMP.
Effect of the alleged presidential pardon: more freedom of maneuver on investments
The alleged grazia presidenziale would have removed some procedural barriers related to previous judicial matters, allowing Hayes to accept public appointments and present himself as an active investor. An interesting aspect is the potential improvement in access to deal‑flow, regulated networks, and faster decision-making processes. However, the normal verifiche di conformità required for governance roles in the healthcare sector remain.
Crypto yes, but not only: Maelstrom remains focused on digital
Despite the growing attention towards biotech, Hayes does not abandon the perimeter of cryptocurrencies. The family office, Maelstrom, continues to support Bitcoin developers and companies with tokens on the balance sheet, maintaining a barbell strategy that combines digital assets and investments in life sciences.
Clinics abroad and cell therapy: opportunities and risks
The focus on Messico and Thailandia indicates the search for environments with sometimes more permissive regulations compared to the USA and Europe. This can accelerate innovation, but it also requires greater transparency, traceability, and solid clinical data.
Regulatory framework comparison
- USA (FDA): the Food and Drug Administration indicates that many stem cell therapies are not approved and may present risks; see the consumer alert from the FDA.
- EU (EMA): advanced therapies fall into the ATMP category and require centralized authorization; the overview from the EMA is available.
- Mexico (COFEPRIS): the regulator COFEPRIS has previously recalled unauthorized offers of cellular therapies.
- Thailand (Thai FDA): the Thai FDA regulates biological products by requiring registrations and trials for therapeutic indications.
For investors, the message remains clear: innovation and first-mover advantage can open opportunities, but regulatory, clinical, and reputational risks remain high. Without robust clinical evidence, returns could be delayed or, simply, not materialize.
Essential Timeline
- In recent years: legal proceedings related to BitMEX and related restrictions;
- Recently: alleged granting of a presidential pardon that would have removed constraints for public appointments;
- Ongoing: Hayes’ entry into the board and investment in a company active in stem cells with operations in Mexico/Thailand;
- In parallel: Maelstrom continues with grants to developers and participation in crypto-native projects.
Impact on the market: more capital, more competition, more due diligence
The influx of crypto capital into longevity biotech could compress development times, shifting the focus to controlled trials, measurable clinical endpoints, and stricter governance. Competition for talent is growing, and the cost of accessing samples and GMP infrastructure is increasing. A delicate point remains open: who will be able to afford expensive and, in many cases, still experimental therapies?
What is confirmed vs what is not verified
What is confirmed
- Hayes’s interest in longevity and regenerative medicine;
- The maintenance of crypto assets through Maelstrom;
- The stringent regulatory context in USA/UE for cellular therapies, highlighted by the consumer alert from the FDA and EMA regulations;
- The involvement of well-known crypto investors, such as Buterin and Armstrong, in the field of longevity.
What is not verified
- The name of the stem cell company in which Hayes invests and the documentation related to his entry into the board (press release, filing, or official registration);
- The exact entity of the participation (percentage or range) and the precise date of the operation;
- Direct statements from Hayes with verifiable sources (interview, official post, or public transcript);
- Clinical details on the treatments received (indications, protocols, published evidence of efficacy and safety).
The overall picture
Hayes’s choice signals a broader dynamic: capital originating in the crypto sector is exploring new frontiers of healthcare innovation. An interesting aspect is the convergence between digital finance and biotech, which can accelerate development but requires rigorous clinical trials, regulatory oversight, and attention to equity of access. Only in this way can the race for longevity move from narrative to concrete, measurable, and, above all, replicable results.
Sources and insights
- https://www.fda.gov/consumers/consumer-updates/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
- https://stemcells.nih.gov/
- https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
- https://www.gob.mx/cofepris
- https://www.fda.moph.go.th/
- https://sens.org
- https://www.newlimit.com/
- https://www.sec.gov/edgar/search/
